A carregar...

Tildrakizumab in the treatment of psoriasis – literature review

Psoriasis is a chronic, inflammatory disease. The incidence of its occurrence in developed countries is 1–4%. The aim of this study is to present the current state of knowledge and characterize the antibody tildrakizumab, which in March 2018 was approved by the FDA agency for use in adult patients w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Reumatologia
Autor principal: Banaszczyk, Katarzyna
Formato: Artigo
Idioma:Inglês
Publicado em: Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2019
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6753595/
https://ncbi.nlm.nih.gov/pubmed/31548750
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/reum.2019.87620
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!